{"product_id":"alzheimers-disease-targets-for-new-clinical-diagnostic-and-therapeutic-strategies-9781439827086","title":"Alzheimer's Disease: Targets for New Clinical Diagnostic and Therapeutic Strategies","description":"\u003cp\u003e • Author(s): Renee D. Wegrzyn\u003cbr\u003e • Publisher: Taylor \u0026amp; Francis\u003cbr\u003e • Publisher Imprint: CRC Press\u003cbr\u003e • BISAC: Neurology\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eIn recent years, a tremendous amount of effort has been focused on better understanding the fundamentals of Alzheimer's disease (AD) to facilitate early and accurate diagnosis and appropriately targeted therapeutic treatments. \u003cstrong\u003eAlzheimer's Disease: Targets for New Clinical, Diagnostic, and Therapeutic Strategies\u003c\/strong\u003e provides a detailed synopsis of the current state of the art of diagnostics and therapeutics and identifies emerging technologies and molecules that show promise in the management and treatment of AD.\u003c\/p\u003e\u003cp\u003eWith contributions from experts drawn from academia, clinical practice, and the biotechnology and pharmaceutical industries, the book explores: \u003c\/p\u003e\u003cul\u003e \u003cp\u003e \u003c\/p\u003e \u003cli\u003eThe basis of AD and the role of Aβ oligomers in development of disease\u003c\/li\u003e \u003cli\u003eExisting and emerging \u003cem\u003ein vitro\u003c\/em\u003e biomarker-based methodologies for the diagnosis of AD, focusing on genetic, biochemical, and conformational strategies\u003c\/li\u003e \u003cli\u003e \u003cem\u003eIn vivo\u003c\/em\u003e imaging diagnostic approaches\u003c\/li\u003e \u003cli\u003eEvolving diagnostic criteria, health regulatory guidelines, biomarkers in clinical trials, and available and emerging therapies\u003c\/li\u003e \u003cli\u003eRecent progress in small-molecule disease-modifier drug discovery efforts for AD, specifically in the areas of Aβ, tau, and emerging neuroprotective\/neurorepair approaches\u003c\/li\u003e \u003cli\u003eHow a case study of AD raises issues regarding clinical and pathologic criteria, risk factors, and the amyloid hypothesis\u003c\/li\u003e \u003cli\u003eThe molecular conformational factors that govern the pathogenicity of aggregating proteins, and how these factors could represent new targets for disease-modifying therapies\u003c\/li\u003e \u003cli\u003eThe latest epidemiological, pathological, biochemical, and behavioral studies that may shed some light on the risk of developing AD and similar dementias after traumatic brain injury\u003c\/li\u003e \u003c\/ul\u003e\u003cp\u003eExamining current hypotheses and suggesting possible new approaches to therapeutic clinical applications, this volume paves the way for a robust pipeline of therapeutics to combat not only AD, but a whole host of other neurodegenerative diseases.\u003c\/p\u003e","brand":"Taylor \u0026 Francis","offers":[{"title":"Hardcover","offer_id":45236005503127,"sku":"9781439827086","price":14111.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0666\/3471\/1191\/files\/9781439827086.webp?v=1769211606","url":"https:\/\/atlanticbooks.com\/products\/alzheimers-disease-targets-for-new-clinical-diagnostic-and-therapeutic-strategies-9781439827086","provider":"Atlantic Books","version":"1.0","type":"link"}